Patents by Inventor Tamera B. Gooding

Tamera B. Gooding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11541075
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: January 3, 2023
    Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
  • Publication number: 20210213043
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Application
    Filed: August 26, 2020
    Publication date: July 15, 2021
    Applicant: Anika Therapeutics, Inc.
    Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
  • Publication number: 20190183920
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Application
    Filed: July 20, 2018
    Publication date: June 20, 2019
    Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
  • Publication number: 20160082038
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Application
    Filed: July 24, 2015
    Publication date: March 24, 2016
    Inventors: Tamera B. GOODING, Stephen J. KENNEDY, Charles H. SHERWOOD
  • Patent number: 8323617
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: December 4, 2012
    Assignee: Anika Therapeutics, Inc.
    Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
  • Patent number: 8124120
    Abstract: Disclosed are hyaluronic acid (HA) compositions including crosslinked, water-insoluble, hydrated HA gel particles. Also disclosed are methods of making the HA compositions, and methods of using the HA composition to augment tissue in a subject.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 28, 2012
    Assignee: Anika Therapeutics, Inc.
    Inventors: Khalid K. Sadozai, Tamera B. Gooding, Kyle Bui, Charles H. Sherwood
  • Publication number: 20110312912
    Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 22, 2011
    Applicant: ANIKA THERAPEUTICS, INC.
    Inventors: Tamera B. GOODING, Stephen J. KENNEDY, Charles H. SHERWOOD